Piramal Pharma Limited announced its financial results for Q3, with a Profit Before Tax of ₹154.93 crore. Revenue from operations stood at ₹1,195.81 crore. The Board approved these results on January 28, 2026. The company continues to monitor labor code changes and their financial impact. The results reflect standalone financials. Earnings per share was ₹0.97.
Q3 Financial Highlights
Piramal Pharma Limited (PPL) has released its standalone financial results for the third quarter. Key figures include:
- Revenue from operations: ₹1,195.81 crore
- Total Income: ₹1,291.96 crore
- Profit before tax: ₹154.93 crore
- Net Profit after tax: ₹128.91 crore
Basic EPS stood at ₹0.97 for Q3.
Nine-Month Performance
The company’s performance over the nine-month period shows the following:
- Revenue from operations: ₹3,292.95 crore
- Total Income: ₹3,771.99 crore
- Profit before tax: ₹544.92 crore
- Net Profit after tax: ₹438.38 crore
Exceptional Items and Labour Codes
The company noted an exceptional item related to the impact of new labor codes, amounting to ₹26.94 crores. Piramal Pharma continues to assess the implications of these changes and will account for them appropriately.
Consolidated Financials: Key Figures
Piramal Pharma Limited also presented its consolidated financial results with highlights including:
- Revenue from operations: ₹2,139.87 crore
- Net Loss after tax: (₹136.19) crore
Source: BSE
